Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial
Digital
- Autores:
-
Gerstein, Hertzel C.
Colhoun, Helen M.
Dagenais, Gilles R.
Diaz, Rafael
Lakshmanan, Mark
Pais, Prem
Probstfield, Jeffrey
Riesmeyer, Jeffrey S.
Riddle, Matthew C.
Rydén, Lars
Xavier, Denis
Messan Atisso, Charles
Dyal, Leanne
Hall, Stephanie
Rao-Melacini, Purnima
Wong, Gloria
Avezum, Alvaro
Basile, Jan
Chung, Namsik
Conget, Ignacio
Cushman, William C.
Franek, Edward
Hancu, Nicolae
Hanefeld, Markolf
Holt, Shaun
Jansky, Petr
Keltai, Matyas
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Cardona-Munoz, Ernesto German
Pirags, Valdis
Pogosova, Nana
Raubenheimer, Peter J.
Shaw, Jonathan E.
Sheu, Wayne H-H.
Temelkova-Kurktschiev, Theodora
The REWIND Investigators
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2019
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/5693
- Acceso en línea:
- https://repositorio.udes.edu.co/handle/001/5693
- Palabra clave:
- Rights
- closedAccess
- License
- Copyright © 2019 Elsevier Ltd. All rights reserved.
| id |
RUDES2_88384ddf2b3fd02cc58141aac7c6ca0d |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/5693 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| title |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| spellingShingle |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| title_short |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| title_full |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| title_fullStr |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| title_full_unstemmed |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| title_sort |
Dulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial |
| dc.creator.fl_str_mv |
Gerstein, Hertzel C. Colhoun, Helen M. Dagenais, Gilles R. Diaz, Rafael Lakshmanan, Mark Pais, Prem Probstfield, Jeffrey Riesmeyer, Jeffrey S. Riddle, Matthew C. Rydén, Lars Xavier, Denis Messan Atisso, Charles Dyal, Leanne Hall, Stephanie Rao-Melacini, Purnima Wong, Gloria Avezum, Alvaro Basile, Jan Chung, Namsik Conget, Ignacio Cushman, William C. Franek, Edward Hancu, Nicolae Hanefeld, Markolf Holt, Shaun Jansky, Petr Keltai, Matyas Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Cardona-Munoz, Ernesto German Pirags, Valdis Pogosova, Nana Raubenheimer, Peter J. Shaw, Jonathan E. Sheu, Wayne H-H. Temelkova-Kurktschiev, Theodora The REWIND Investigators |
| dc.contributor.author.none.fl_str_mv |
Gerstein, Hertzel C. Colhoun, Helen M. Dagenais, Gilles R. Diaz, Rafael Lakshmanan, Mark Pais, Prem Probstfield, Jeffrey Riesmeyer, Jeffrey S. Riddle, Matthew C. Rydén, Lars Xavier, Denis Messan Atisso, Charles Dyal, Leanne Hall, Stephanie Rao-Melacini, Purnima Wong, Gloria Avezum, Alvaro Basile, Jan Chung, Namsik Conget, Ignacio Cushman, William C. Franek, Edward Hancu, Nicolae Hanefeld, Markolf Holt, Shaun Jansky, Petr Keltai, Matyas Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Cardona-Munoz, Ernesto German Pirags, Valdis Pogosova, Nana Raubenheimer, Peter J. Shaw, Jonathan E. Sheu, Wayne H-H. Temelkova-Kurktschiev, Theodora The REWIND Investigators |
| dc.contributor.researchgroup.spa.fl_str_mv |
Everest |
| description |
Digital |
| publishDate |
2019 |
| dc.date.issued.none.fl_str_mv |
2019-07-13 |
| dc.date.accessioned.none.fl_str_mv |
2021-11-16T16:35:04Z |
| dc.date.available.none.fl_str_mv |
2021-11-16T16:35:04Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/5693 |
| identifier_str_mv |
doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. |
| url |
https://repositorio.udes.edu.co/handle/001/5693 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
138 |
| dc.relation.citationissue.spa.fl_str_mv |
10193 |
| dc.relation.citationstartpage.spa.fl_str_mv |
131 |
| dc.relation.citationvolume.spa.fl_str_mv |
394 |
| dc.relation.cites.none.fl_str_mv |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. PMID: 31189509. |
| dc.relation.indexed.spa.fl_str_mv |
The Lancet |
| dc.relation.ispartofjournal.spa.fl_str_mv |
The Lancet |
| dc.rights.spa.fl_str_mv |
Copyright © 2019 Elsevier Ltd. All rights reserved. |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| rights_invalid_str_mv |
Copyright © 2019 Elsevier Ltd. All rights reserved. Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by/4.0/ http://purl.org/coar/access_right/c_14cb |
| eu_rights_str_mv |
closedAccess |
| dc.format.extent.spa.fl_str_mv |
8 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
The Lancet |
| dc.publisher.place.spa.fl_str_mv |
London, England |
| dc.source.spa.fl_str_mv |
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31150-X/fulltext |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/60800013-555d-4bbb-a6f9-5e1fd5c68890/download https://repositorio.udes.edu.co/bitstreams/068695b9-35e8-4f88-986c-f1faf901a212/download https://repositorio.udes.edu.co/bitstreams/5d51b802-d602-4cf3-bcd5-7aa56d5af487/download https://repositorio.udes.edu.co/bitstreams/3e07679d-6e99-4217-8c0b-e8e551ee653e/download |
| bitstream.checksum.fl_str_mv |
9623c97049bcfe2dc99e3908d2541bd6 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 eaf63541334c0088161859552d5ef50a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814158546945703936 |
| spelling |
Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Colhoun, Helen M.41617f18-e528-4e15-819a-0a30d7feb185-1Dagenais, Gilles R.f72492d7-dc96-43b0-9237-b00656585504-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Lakshmanan, Marke4d26b36-1c41-49d9-9c19-d57fb2109f53-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Riesmeyer, Jeffrey S.525649f3-d90b-4d73-937c-843315b22916-1Riddle, Matthew C.d5c956b6-8f40-43ca-83bc-4b130c672a99-1Rydén, Larsfbe7a352-5488-4e8a-866d-b966ed6789b4-1Xavier, Denis88c9cf48-fa3b-45c6-be03-2cc79e59289d-1Messan Atisso, Charles42893105-5995-4c81-b612-a885c11a8170-1Dyal, Leanne2c1519ed-7131-4c64-ae64-60293a636b7c-1Hall, Stephanie76425501-41fc-4b68-bd22-1a38e1e3d160-1Rao-Melacini, Purnima4a704681-2187-4ddd-b2c1-f8e681c77274-1Wong, Gloria066cbc15-6c79-4e97-9d6e-dc00cd2d8906-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Chung, Namsik9a0d8ed9-0c50-442d-baa7-35828186bb71-1Conget, Ignacioc0327a53-3097-438b-9a40-d441f3c20758-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Franek, Edwardc8fa48cd-c0c0-4e99-ad2b-29843fba16c4-1Hancu, Nicolae65f98f93-ff67-40b8-bfc7-c1fed7923dd1-1Hanefeld, Markolf411c9d9d-d3a2-4a87-b8e7-dbd8bc7c968e-1Holt, Shaun42264558-8dfa-4004-ad7d-065174c245a2-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Cardona-Munoz, Ernesto Germane71ec18c-d00c-4fff-805b-0909d8b13e07-1Pirags, Valdisc43a25fe-51ee-4b71-863e-54b03868e125-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Raubenheimer, Peter J.260f749c-e594-4273-a34d-e926010f883c-1Shaw, Jonathan E.bee14056-7326-4051-b756-4d809e9c79f8-1Sheu, Wayne H-H.d377b549-9728-486e-820f-f5e9d3ba834b-1Temelkova-Kurktschiev, Theodoraa08e998d-95f2-4139-ae16-bd8009965b60-1The REWIND Investigators7f5b8bd2-2d41-4aba-be23-313634bab624-1Everest2021-11-16T16:35:04Z2021-11-16T16:35:04Z2019-07-13DigitalBackground: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease. Methods: REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo and followed up at least every 6 months for outcomes. Urinary albumin-to-creatinine ratios (UACRs) and estimated glomerular filtration rates (eGFRs) were estimated from urine and serum values measured in local laboratories every 12 months. The primary outcome (first occurrence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes), secondary outcomes (including a composite microvascular outcome), and safety outcomes of this trial have been reported elsewhere. In this exploratory analysis, we investigate the renal component of the composite microvascular outcome, defined as the first occurrence of new macroalbuminuria (UACR >33·9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01394952. Findings: Between Aug 18, 2011, and Aug 14, 2013, 9901 participants were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). At baseline, 791 (7·9%) had macroalbuminuria and mean eGFR was 76·9 mL/min per 1·73 m2 (SD 22·7). During a median follow-up of 5·4 years (IQR 5·1-5·9) comprising 51 820 person-years, the renal outcome developed in 848 (17·1%) participants at an incidence rate of 3·5 per 100 person-years in the dulaglutide group and in 970 (19·6%) participants at an incidence rate of 4·1 per 100 person-years in the placebo group (hazard ratio [HR] 0·85, 95% CI 0·77-0·93; p=0·0004). The clearest effect was for new macroalbuminuria (HR 0·77, 95% CI 0·68-0·87; p<0·0001), with HRs of 0·89 (0·78-1·01; p=0·066) for sustained decline in eGFR of 30% or more and 0·75 (0·39-1·44; p=0·39) for chronic renal replacement therapy. Interpretation: Long-term use of dulaglutide was associated with reduced composite renal outcomes in people with type 2 diabetes.Ciencias Médicas y de la Salud8 papplication/pdfdoi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.https://repositorio.udes.edu.co/handle/001/5693engThe LancetLondon, England13810193131394Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. PMID: 31189509.The LancetThe LancetCopyright © 2019 Elsevier Ltd. All rights reserved.info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by/4.0/http://purl.org/coar/access_right/c_14cbhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31150-X/fulltextDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial.pdfDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial.pdfapplication/pdf230152https://repositorio.udes.edu.co/bitstreams/60800013-555d-4bbb-a6f9-5e1fd5c68890/download9623c97049bcfe2dc99e3908d2541bd6MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/068695b9-35e8-4f88-986c-f1faf901a212/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial.pdf.txtDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/5d51b802-d602-4cf3-bcd5-7aa56d5af487/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial.pdf.jpgDulaglutide and renal outcomes in type 2 diabetes. An exploratory analysis of the REWIND randomised, placebo-controlled trial.pdf.jpgGenerated Thumbnailimage/jpeg6939https://repositorio.udes.edu.co/bitstreams/3e07679d-6e99-4217-8c0b-e8e551ee653e/downloadeaf63541334c0088161859552d5ef50aMD54001/5693oai:repositorio.udes.edu.co:001/56932023-10-09 18:14:19.149https://creativecommons.org/licenses/by/4.0/Copyright © 2019 Elsevier Ltd. All rights reserved.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |